Buscar
Mostrando ítems 1-10 de 3677
Clinical and therapeutic relevance of the metabolic oncogene fatty acid synthase in HER2+ breast cancer
(Universidad de Murcia, 2017-07)
Fatty acid synthase (FASN) is a key lipogenic enzyme for de novo fatty acid biosynthesis and a druggable metabolic oncoprotein that is activated in most human cancers. We evaluated whether the HER2-driven lipogenic phenotype ...
Working together for the family: Determination of HER oncogene co-amplifications in breast cancer
(Impact Journals, 2020-07)
HER2 is a well-studied tyrosine kinase (TK) membrane receptor which functions as a therapeutic target in invasive ductal breast carcinomas (IDC). The standard of care for the treatment of HER2-positive breast is the antibody ...
Clinicopathological factors associated with the amplification of the HER2 /neu gene in patients with breast cancer HER2 2+Factores clinicopatológicos asociados a la amplificación del gen HER2/neu en pacientes con cáncer de mama HER2 2+
(Universidad Nacional Mayor de San Marcos, Facultad de Medicina Humana, 2018)
Textual Trappings in Emily Dickinson's Selected Poems
(Universidad del Zulia, 2020)
HER-2 positive breast carcinoma associated pathological characteristicsCaracterísticas patológicas asociadas al carcinoma de mama HER-2 positivo
(Universidad Nacional Mayor de San Marcos, Facultad de Medicina Humana, 2005)
Neoadjuvant pertuzumab in non-metastatic HER2-positive breast tumors: Multicentric study in Peru (NeoHer)
(Spandidos Publications, 2022)
Several clinical trials have demonstrated the benefit of adding pertuzumab to trastuzumab plus neoadjuvant chemotherapy in the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer. The ...
Correlation of Her-2 Expression with Clinicopathological Characteristics in Invasive Ductal Breast Cancer Patients
(Academia Nacional de Medicina venezolana., 2022)
Fatty acid synthase confers tamoxifen resistance to ER+/HER2+ breast cancer
(Multidisciplinary Digital Publishing Institute, 2021-03)
Overactivation of the human epidermal growth factor receptor 2 (HER2) is one of the main drivers of tamoxifen resistance in estrogen receptor (ER)-positive breast cancer patients. Combined targeting of HER2 and ER, however, ...